We are updating the design of this site. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

Endometriosis Patients Undergoing Quinagolide Treatment

This study has been completed.
Sponsor:
ClinicalTrials.gov Identifier:
NCT00625950
First Posted: February 29, 2008
Last Update Posted: January 12, 2009
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Information provided by:
Instituto Valenciano de Infertilidad, IVI VALENCIA
February 20, 2008
February 29, 2008
January 12, 2009
February 2008
April 2008   (Final data collection date for primary outcome measure)
observation of three month treatment with Quinagolida in endometriosis patients [ Time Frame: onset and three months after onset ]
Same as current
Complete list of historical versions of study NCT00625950 on ClinicalTrials.gov Archive Site
Not Provided
Not Provided
Not Provided
Not Provided
 
Endometriosis Patients Undergoing Quinagolide Treatment
Effect of Treatment With Agonist Dopaminergics on Endometriosic Lesions.
Dopamine agonists, such as quinagolide, are able to act on the VEGFR-2 blocking antibodies, diminishing Vascular Endothelial Growth Factor effect on angiogenesis in human endometriotic lesions.
Not Provided
Interventional
Phase 4
Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Health Services Research
  • Hyperprolactinemia
  • Endometriosis
Procedure: ENDOMETRIAL BIOPSY
Two routine laparoscopies in period of three months with endometrial biopsy comparative study performed.
Not Provided
Gómez R, Abad A, Delgado F, Tamarit S, Simón C, Pellicer A. Effects of hyperprolactinemia treatment with the dopamine agonist quinagolide on endometriotic lesions in patients with endometriosis-associated hyperprolactinemia. Fertil Steril. 2011 Mar 1;95(3):882-8.e1. doi: 10.1016/j.fertnstert.2010.10.024. Epub 2010 Nov 5.

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
5
May 2008
April 2008   (Final data collection date for primary outcome measure)

Inclusion Criteria:

  • Hyperprolactinemia
  • Unexplained infertility
  • Endometriosis
Sexes Eligible for Study: Female
18 Years to 37 Years   (Adult)
No
Contact information is only displayed when the study is recruiting subjects
Spain
 
 
NCT00625950
VLC-AP-10208-208-1
No
Not Provided
Not Provided
Prof. Dr. Antonio Pellicer, Instituto Valenciano de Infertilidad, Spain
Instituto Valenciano de Infertilidad, IVI VALENCIA
Not Provided
Not Provided
Instituto Valenciano de Infertilidad, IVI VALENCIA
January 2009

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP